<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401423</url>
  </required_header>
  <id_info>
    <org_study_id>AAAT0535</org_study_id>
    <nct_id>NCT04401423</nct_id>
  </id_info>
  <brief_title>TXA127 for the Treatment of Severe COVID-19</brief_title>
  <official_title>Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if administration of angiotensin-(1-7) (TXA127)
      prevents acute kidney injury and deterioration into multi-organ failure in patients with
      severe COVID-19. Participants will undergo a 10-day treatment with either placebo or study
      drug. The drug will be administered intravenously for 3 hours once each day for 10 days
      consecutively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corona virus disease 2019 (COVID-19) has been associated with severe respiratory and
      multiorgan failure. Research shows that COVID-19 reduces levels of angiotensin-converting
      enzyme-2 (ACE-2), an enzyme that converts angiotensin II to angiotensin 1-7 (known as
      TXA127). COVID-19 reduces levels of ACE-2 and therefore angiotensin 1-7 and as a result,
      angiotensin II levels are going to be increased. Many clinical observations in COVID-19 have
      shown the high incidence of acute kidney injury that may be due to excessive levels of
      angiotensin II. The investigators hypothesize that administration of angiotensin (1-7)
      replaces levels of ACE-2 in COVID-19 and thereby ameliorates deterioration of multi-organ
      failure and specifically acute kidney injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded, placebo-control, randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of serum creatinine</measure>
    <time_frame>Day 1 and Day 10</time_frame>
    <description>Calculated from baseline (at enrollment) to end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants requiring intubation and ventilatory support</measure>
    <time_frame>Up to Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of deceased participants</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring dialysis</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring a vasopressors</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood inflammatory markers</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in supplemental oxygen requirements</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>TXA127</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one 3-hour dosage (0.5 mg/kg), intravenously, for 10 days consecutively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive one 3-hour dosage (0.5 mg/kg), intravenously, for 10 days consecutively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TXA127</intervention_name>
    <description>0.5 mg/kg per day</description>
    <arm_group_label>TXA127</arm_group_label>
    <other_name>angiotensin-(1-7)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mg/kg per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe COVID-19: Adult patients admitted to the hospital through the Emergency
             Department (ED) requiring oxygen therapy (any level) to maintain oxygen saturation
             (SaO2) &gt; 90%

          -  COVID positive by polymerase chain reaction (PCR) on hospital admission

          -  Hospitalized patients aged 18 years or greater

        Exclusion Criteria:

          -  Pre-existing chronic kidney disease

          -  New use of or change in dose of ACE-inhibitors or angiotensin receptor blocker (ARB)
             within the last 6 months

          -  Acute kidney injury at the time of enrollment defined as either increase pf serum
             creatinine by more than 50% or 0.3 mg/dL above baseline or estimated creatinine
             clearance (by MDRD) of less than 60 ml/min (if no baseline serum creatinine available)

          -  Pregnant and breastfeeding women

          -  Contraindicated medications: new use or change of medications from start of trial
             (start of an ACE inhibitor or ARB within 6 months of trial).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanine D'Armiento, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine in Anesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeanine D'Armiento, MD, PhD</last_name>
    <phone>212-305-3745</phone>
    <email>jmd12@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Fonseca</last_name>
    <phone>212-305-3745</phone>
    <email>lf2560@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine M D'Armiento, MD, PhD</last_name>
      <phone>212-305-3745</phone>
      <email>jmd12@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura D Fonseca, MS</last_name>
      <phone>212-305-3745</phone>
      <email>lf2560@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeanine M D'Armiento, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Jeanine D'Armiento</investigator_full_name>
    <investigator_title>Associate Professor of Medicine (in Anesthesiology)</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>multi-organ failure</keyword>
  <keyword>acute kidney injury</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin I (1-7)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

